| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c6329f2bcf04665c49be0ff368663d4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J1-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J3-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J1-035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J3-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J1-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate |
2021-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76a794968810fbad65ea4635d3cf70c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12fc021a5e50c6d6f80516b9a9fff088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97af39ef1f339ff4609c9ec261b16658
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_944a936010e035720ced46f604f34e53 |
| publicationDate |
2022-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022040196-A1 |
| titleOfInvention |
Pharmaceutical Composition of Chlordiazepoxide and Clidinium Combination |
| abstract |
The present invention relates to a stable pharmaceutical composition comprising a combination of chlordiazepoxide hydrochloride and clidinium bromide and one or more pharmaceutically acceptable excipients, wherein the composition is in the form of solid oral dosage forms like capsule and sachet. The technical challenges like undesirable impurities in dosage form were successfully controlled by using: a) low moisture excipients; and b) formulation development under controlled temperature and controlled humidity conditions. The formulations as per the present invention are stable and exhibit desired pharmaceutical technical attributes like assay and dissolution. The prepared formulations are useful for the treatment of gastrointestinal disorders and various other therapeutic indications as described herein. |
| priorityDate |
2020-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |